All In Biotech

Drug Trial Radar · NCT01817322

Kidney Graft Function Under the Immunosuppression Strategies

Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral®(Cyclosporine) and Standard Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral®(Cyclosporine) and Reduced Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Oct 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Jun 2011

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate that cyclosporine-sparing immunosuppressions with the standard dose of Enteric-Coated Mycophenolate Sodium would preserve renal graft function after transplantation without an increase of incidences of adverse events, such as biopsy confirmed acute rejection, local or systemic infections, and bone marrow suppression.

Conditions

  • Chronic Renal Disease

Interventions

  • Standard Dose of Myfortic and Reduced Dose of MyforticDrug

    Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)

  • Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental groupDrug

    500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.

  • Basiliximab injected both control group and experimental groupDrug

    The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. eGFR (abbreviated MDRD equation)Time frame: 6 months after transplantation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.